GlaxoSmithKline (GSK) and Teva settled their almost decade-long skinny label dispute after landing, one last time, back in the District of Delaware where Teva had sought a new trial until yesterday when the Court granted the parties’ Joint Stipulation to Dismiss (Case No. 14-cv-878) filed on Friday.

The patent case involving heart failure treatment followed a tortured path including a jury verdict of infringement and a $235M damages award in 2017 that were overruled by Judge Stark, then two reversals at the Federal Circuit including a splintered full bench opinion, and a refusal by the Supreme Court to hear the case in 2023.  

For the parties at least, all may be well that ends well, though questions about the law of skinny labels live on in the Hikma v. Amarin case, which the Supreme Court agreed to hear last month (Case No. 2023-1169).